文献速递炎症性肠病

多中心随机试验:粪菌移植诱导轻中度克罗恩病缓解的初步结果

Preliminary Results From a Multicenter, Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's Disease.
PubMed 文献 · Am J Gastroenterol · 2024-11-12

这项双盲、安慰剂对照试验在3个加拿大中心纳入轻中度克罗恩病患者,比较粪菌移植(FMT)与安慰剂的疗效。第8周时,FMT组0%(0/15)达到临床和内镜联合缓解的主要终点,安慰剂组为8.3%(1/11),试验因无效提前终止。FMT组活动受限有显著改善,但两组临床或内镜应答无差异。

要点

  • 第8周FMT组主要终点临床和内镜联合缓解为0%(0/15),安慰剂组为8.3%(1/11)。
  • 两组临床应答和内镜应答均无差异,每组各有1例克罗恩病加重。
  • 仅FMT组活动受限有显著改善;两组微生物多样性或组成无显著变化。

核心结论

  • 在本研究的FMT方案下,FMT未能有效诱导克罗恩病临床和内镜缓解。
  • 未来研究可能采用更长干预、抗生素预处理、优化供受体配对、伴随抗炎饮食及生物制剂或小分子药物等策略以提高应答。

研究设计与样本

  • 双盲、安慰剂对照试验,在3个加拿大中心开展。
  • 随机分配轻中度克罗恩病患者接受FMT或安慰剂;首次经结肠镜给药,随后每周口服胶囊共7周。
  • 主要终点为第8周临床和内镜联合缓解;次要终点包括临床和内镜应答、不良事件及健康相关生活质量。
  • 2017年7月至2021年6月,FMT组随机21例,安慰剂组13例;试验因无效提前终止。

主要发现

  • 符合方案分析中,第8周FMT组0%(0/15)达到主要终点,安慰剂组8.3%(1/11)。
  • 两组临床应答和内镜应答均无差异。
  • 每组各有1例患者克罗恩病加重。
  • 两组健康相关生活质量均有统计学显著改善,但仅FMT组活动受限有显著下降。
  • 微生物多样性或组成无显著变化;达到临床应答的患者粪便微生物组成更接近其供体。

局限性

  • 试验因无效提前终止。
  • 未来研究可能采用其他策略以提高治疗应答,包括更长干预、抗生素预处理、优化供受体配对、伴随抗炎饮食及生物制剂或小分子药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fecal microbiota transplantation (FMT) has shown promise at inducing remission in ulcerative colitis. This study is the first of its kind to evaluate the efficacy and safety of FMT at inducing remission in Crohn's disease (CD). METHODS: This double-blind, placebo-controlled trial was conducted in 3 Canadian academic centers; randomized patients with mild-to-moderate CD received FMT or placebo. The first treatment was administered by colonoscopy followed by weekly oral capsules for 7 weeks. Primary end point was clinical and endoscopic remission at week 8. Secondary outcomes included clinical and endoscopic response, adverse events, and health-related quality of life using generic and disease-specific instruments. RESULTS: From July 2017 to June 2021, 21 and 13 patients were randomized to FMT and placebo groups, respectively. The trial terminated early due to futility. At week 8, 0% (0/15) of patients in the FMT group versus 8.3% (1/11) in the placebo group reached the primary end point of combined clinical and endoscopic remission as per protocol analysis. There were no differences between the groups in clinical or endoscopic responses. One patient in each group had worsening of CD. Although both groups experienced statistically significant improvements in health-related quality of life, only the FMT group had a significant decrease in activity impairment. Although there were no significant changes in microbial diversity or composition, patients who achieved clinical response became more similar to their donors in stool microbial composition. DISCUSSION: FMT was not effective at inducing clinical and endoscopic remission in CD using the FMT regimen in this study. Future studies may use other strategies to enhance treatment response, including longer intervention, antibiotic pretreatment, optimized donor-recipient pairing, and concomitant anti-inflammatory diet, and biologic or small molecule therapies.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kao D, Wong K, Jijon H, et al. Preliminary Results From a Multicenter, Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's Disease. Am J Gastroenterol. 2024. PMID: 39530534. doi:10.14309/ajg.0000000000003196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。